DelveInsight’s “Wet AMD Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Wet AMD Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Wet AMD market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Wet AMD: Overview
Wet AMD, also called neovascular AMD, only accounts for about 10% of the total macular degeneration cases, most of the legal blindness related to macular degeneration results from it. Age-related macular degeneration (AMD) is a leading cause of severe, irreversible blindness in developed countries worldwide, profoundly affecting individuals’ quality of life. Increasing life expectancy, bringing growth in the number of reported cases, adds a significant burden on the health care systems with the expensive current standard-of-care. Wet AMD is a type of AMD which is characterized by abrupt central vision loss caused by abnormal blood vessels that bleed or leak fluid, which may swell and damage the macula.
Get access to a free copy of our latest sample report @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market
Some of the key facts of Wet AMD Market
According to Pennigton et al. (2016), approximately 11 million individuals are affected with AMD in the US alone, with a global prevalence of 170 million. AMD is thereby the leading cause of visual disability in the industrialized world and the third leading cause globally.
According to Nakata et al. (2012), the prevalence of early AMD among adult Japanese persons was similar to the rates in white populations. The prevalence of late AMD in Japanese people aged
According to DelveInsight’s analysis, wet AMD is more prominent in females in comparison to males.
Wet AMD Market
Wet AMD market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of Wet AMD in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Wet AMD market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Wet AMD market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Wet AMD Epidemiology
The epidemiology section covers insights about the historical and current Wet AMD patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Wet AMD Drugs & Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Wet AMD market or expected to get launched in the market during the study period. The analysis covers Wet AMD market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Wet AMD Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Wet AMD Therapeutics Analysis
Companies all over the globe are persistently working toward the development of new treatment therapies for Wet AMD. The launch of the emerging therapies is expected to transform the treatment dynamics in the coming years.
Wet AMD Companies includes-
Chengdu Kanghong Biotech
Kodiak Sciences Inc.
Ribomic USA Inc, and others
Wet AMD Therapies includes-
Macugen, and others
View Detailed Report of key players and therapies @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market
Table of content
Competitive Intelligence Analysis
Market Overview at a Glance
Disease Background and Overview
Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Key Endpoints of Wet AMD Treatment
Seven Major Market Analysis
7MM: Market Outlook
Access and Reimbursement Overview
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States